1. Home
  2. CBNK vs CAPR Comparison

CBNK vs CAPR Comparison

Compare CBNK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

N/A

Current Price

$41.23

Market Cap

560.3M

Sector

Finance

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$8.99

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBNK
CAPR
Founded
1974
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.3M
584.9M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
CBNK
CAPR
Price
$41.23
$8.99
Analyst Decision
Hold
Buy
Analyst Count
5
10
Target Price
★ $44.08
$27.25
AVG Volume (30 Days)
116.3K
★ 3.8M
Earning Date
10-26-2026
11-10-2026
Dividend Yield
★ 1.36%
N/A
EPS Growth
★ 60.85
N/A
EPS
★ 2.40
N/A
Revenue
N/A
N/A
Revenue This Year
$8.98
N/A
Revenue Next Year
$10.68
$85.77
P/E Ratio
$17.21
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$26.40
$2.96
52 Week High
$44.76
$40.37

Technical Indicators

Market Signals
Indicator
CBNK
CAPR
Relative Strength Index (RSI) 49.05 52.58
Support Level $35.70 $7.78
Resistance Level $44.76 $10.62
Average True Range (ATR) 0.81 1.05
MACD -0.31 0.07
Stochastic Oscillator 3.19 51.87

Price Performance

Historical Comparison
CBNK
CAPR

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: